These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 19429511)

  • 1. The histamine H3 receptor as a therapeutic drug target for CNS disorders.
    Gemkow MJ; Davenport AJ; Harich S; Ellenbroek BA; Cesura A; Hallett D
    Drug Discov Today; 2009 May; 14(9-10):509-15. PubMed ID: 19429511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histamine H3 receptor as a drug discovery target.
    Berlin M; Boyce CW; Ruiz Mde L
    J Med Chem; 2011 Jan; 54(1):26-53. PubMed ID: 21062081
    [No Abstract]   [Full Text] [Related]  

  • 3. Histamine H3 and H4 receptors as novel drug targets.
    Tiligada E; Zampeli E; Sander K; Stark H
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1519-31. PubMed ID: 19758107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The histamine H(3) receptor: a target for new drugs].
    Arrang JM
    Ann Pharm Fr; 2003 May; 61(3):173-84. PubMed ID: 12714930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H3 receptor antagonists/inverse agonists as anti-obesity agents.
    Hancock AA
    Curr Opin Investig Drugs; 2003 Oct; 4(10):1190-7. PubMed ID: 14649210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders.
    Passani MB; Lin JS; Hancock A; Crochet S; Blandina P
    Trends Pharmacol Sci; 2004 Dec; 25(12):618-25. PubMed ID: 15530639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in histamine H3 receptor antagonists/inverse agonists.
    Łazewska D; Kieć-Kononowicz K
    Expert Opin Ther Pat; 2010 Sep; 20(9):1147-69. PubMed ID: 20716022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Possible roles of brain histamine H3 receptors and the pharmacology of its ligands].
    Onodera K; Watanabe T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Apr; 15(2):87-102. PubMed ID: 7796325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview: H3 histamine receptor isoforms: new therapeutic targets in the CNS?
    Chazot PL; Hann V
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1428-31. PubMed ID: 11890359
    [No Abstract]   [Full Text] [Related]  

  • 10. Several down, a few to go: histamine H3 receptor ligands making the final push towards the market?
    Kuhne S; Wijtmans M; Lim HD; Leurs R; de Esch IJ
    Expert Opin Investig Drugs; 2011 Dec; 20(12):1629-48. PubMed ID: 21992603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders.
    Esbenshade TA; Fox GB; Cowart MD
    Mol Interv; 2006 Apr; 6(2):77-88, 59. PubMed ID: 16565470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system.
    Witkin JM; Nelson DL
    Pharmacol Ther; 2004 Jul; 103(1):1-20. PubMed ID: 15251226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders.
    Parmentier R; Anaclet C; Guhennec C; Brousseau E; Bricout D; Giboulot T; Bozyczko-Coyne D; Spiegel K; Ohtsu H; Williams M; Lin JS
    Biochem Pharmacol; 2007 Apr; 73(8):1157-71. PubMed ID: 17288995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The histaminergic system: a target for innovative treatments of cognitive deficits].
    Motawaj M; Burban A; Davenas E; Gbahou F; Faucard R; Morisset S; Arrang JM
    Therapie; 2010; 65(5):415-22. PubMed ID: 21144476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687).
    McLeod RL; Rizzo CA; West RE; Aslanian R; McCormick K; Bryant M; Hsieh Y; Korfmacher W; Mingo GG; Varty L; Williams SM; Shih NY; Egan RW; Hey JA
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1037-44. PubMed ID: 12649305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H3 antagonists/inverse agonists.
    Hancock AA
    Biochem Pharmacol; 2006 Apr; 71(8):1103-13. PubMed ID: 16513092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The histamine H3 receptor: from gene cloning to H3 receptor drugs.
    Leurs R; Bakker RA; Timmerman H; de Esch IJ
    Nat Rev Drug Discov; 2005 Feb; 4(2):107-20. PubMed ID: 15665857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive activity of the histamine H3 receptor.
    Arrang JM; Morisset S; Gbahou F
    Trends Pharmacol Sci; 2007 Jul; 28(7):350-7. PubMed ID: 17573125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats.
    Medhurst AD; Briggs MA; Bruton G; Calver AR; Chessell I; Crook B; Davis JB; Davis RP; Foley AG; Heslop T; Hirst WD; Medhurst SJ; Ociepka S; Ray A; Regan CM; Sargent B; Schogger J; Stean TO; Trail BK; Upton N; White T; Orlek B; Wilson DM
    Biochem Pharmacol; 2007 Apr; 73(8):1182-94. PubMed ID: 17276409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histamine-selective H3 receptor ligands and cognitive functions: an overview.
    Vohora D
    IDrugs; 2004 Jul; 7(7):667-73. PubMed ID: 15243869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.